Primo Nutraceuticals Inc.
BUGVF
OTC PK
| Weiss Ratings | BUGVF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Unrated | |||
| Risk Index | Unrated | |||
| Risk Grade | U | |||
| Reward Grade | U | |||
| Rating Factors | BUGVF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | Unrated | |||
| Growth Index | Unrated | |||
| Efficiency Index | Unrated | |||
| Solvency Index | Unrated | |||
| Total Return Index | Unrated | |||
| Volatility Index | Unrated | |||
| Beta / Standard Deviation | BUGVF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.00 | |||
| Price History | BUGVF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -- | |||
| 30-Day Total Return | -- | |||
| 60-Day Total Return | -- | |||
| 90-Day Total Return | -- | |||
| Year to Date Total Return | -- | |||
| 1-Year Total Return | -- | |||
| 2-Year Total Return | -- | |||
| 3-Year Total Return | -99.00% | |||
| 5-Year Total Return | -100.00% | |||
| 52-Week High % Change | 0.00% | |||
| 52-Week Low % Change | 0.00% | |||
| Price | BUGVF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $0.00 | |||
| 52-Week Low Price | $0.00 | |||
| 52-Week Low Price (Date) | Jun 07, 2024 | |||
| 52-Week High Price (Date) | Jun 07, 2024 | |||
| Valuation | BUGVF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 25.00 | |||
| Enterprise Value | -- | |||
| Price/Earnings (TTM) | 0.00 | |||
| Earnings Per Share (TTM) | -0.73 | |||
| Earnings Per Share Growth | 2,715.38% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | -- | |||
| Price/Book (Q) | 0.00 | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $0.00 | |||
| Enterprise Value/EBITDA (TTM) | -- | |||
| Enterprise Value/EBIT | -- | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | BUGVF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 9.44M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | BUGVF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 877-517-7816 | |||
| Address | 890 West Pender Street Vancouver, BC V6C 1J9 | |||
| Website | www.primonutraceuticals.com | |||
| Country | Canada | |||
| Year Founded | 2014 | |||
| Profitability | BUGVF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -- | |||
| Profit Margin | -- | |||
| Management Effectiveness | BUGVF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -31.99% | |||
| Return on Equity | -- | |||
| Income Statement | BUGVF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | -- | |||
| Total Revenue (TTM) | -- | |||
| Revenue Per Share | -- | |||
| Gross Profit (TTM) | -- | |||
| EBITDA (TTM) | -- | |||
| EBIT (TTM) | -1.12M | |||
| Net Income (TTM) | -3.92M | |||
| Net Income Avl. to Common (TTM) | -3.92M | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | -75.41% | |||
| EPS Diluted (TTM) | -0.73 | |||
| EPS Diluted Growth (Q YOY) | 22.31% | |||
| Balance Sheet | BUGVF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 7.20K | |||
| Cash Per Share (Q) | $0.00 | |||
| Total Current Assets (Q) | 22.50K | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 404.20K | |||
| Current Ratio (Q) | 0.012 | |||
| Book Value Per Share (Q) | $0.04 | |||
| Total Assets (Q) | 2.30M | |||
| Total Current Liabilities (Q) | 1.90M | |||
| Total Debt (Q) | 335.50K | |||
| Total Liabilities (Q) | 1.90M | |||
| Total Common Equity (Q) | 404.20K | |||
| Cash Flow | BUGVF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -145.00K | |||
| Cash from Financing (TTM) | 1.18M | |||
| Net Change in Cash (TTM) | -20.70K | |||
| Levered Free Cash Flow (TTM) | -262.40K | |||
| Cash from Operations (TTM) | -1.05M | |||
